$YMAB
Y-mAbs Therapeutics Inc

2020 Q4 Form 10-Q Financial Statement

#000155837020012905 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $20.75M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.63M $11.64M $4.700M
YoY Change 111.11% 147.57% 75.37%
% of Gross Profit
Research & Development $24.01M $21.01M $19.66M
YoY Change 42.66% 6.84% 125.2%
% of Gross Profit
Depreciation & Amortization $120.0K $90.00K $50.00K
YoY Change 50.0% 80.0% 400.0%
% of Gross Profit
Operating Expenses $40.84M $32.64M $24.36M
YoY Change 71.89% 34.0% 113.3%
Operating Profit -$20.10M -$32.64M -$24.36M
YoY Change -15.42% 34.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $160.0K -$191.0K $437.0K
YoY Change -74.19% -143.71% -4470.0%
Pretax Income -$19.93M -$32.83M -$23.90M
YoY Change -13.87% 37.37% 109.1%
Income Tax
% Of Pretax Income
Net Earnings -$19.93M -$32.83M -$23.92M
YoY Change -13.84% 37.25% 109.29%
Net Earnings / Revenue -96.06%
Basic Earnings Per Share -$0.82
Diluted Earnings Per Share -$491.4K -$0.82 -$696.0K
COMMON SHARES
Basic Shares Outstanding 40.51M 40.19M
Diluted Shares Outstanding 40.19M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.6M $131.3M $98.20M
YoY Change -44.66% 33.71% -39.87%
Cash & Equivalents $114.6M $131.3M $98.19M
Short-Term Investments
Other Short-Term Assets $7.729M $1.942M $1.400M
YoY Change 60.39% 38.71% -50.0%
Inventory $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $122.4M $133.2M $99.60M
YoY Change -42.27% 33.74% -40.0%
LONG-TERM ASSETS
Property, Plant & Equipment $1.825M $1.888M $3.800M
YoY Change -11.06% -50.32% 1800.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.290M $2.975M $300.0K
YoY Change 789.19% 891.67% 50.0%
Total Long-Term Assets $9.684M $9.986M $4.100M
YoY Change 119.54% 143.56% 925.0%
TOTAL ASSETS
Total Short-Term Assets $122.4M $133.2M $99.60M
Total Long-Term Assets $9.684M $9.986M $4.100M
Total Assets $132.0M $143.2M $103.7M
YoY Change -38.97% 38.09% -37.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.372M $10.32M $7.600M
YoY Change 10.0% 35.79% 11.76%
Accrued Expenses $8.197M $7.570M $6.400M
YoY Change 80.15% 18.28% 156.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.54M $19.78M $14.00M
YoY Change 43.79% 41.26% 50.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.968M $1.923M $3.800M
YoY Change 713.22% -49.39% 80.95%
Total Long-Term Liabilities $1.968M $1.923M $3.800M
YoY Change 713.22% -49.39% 80.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.54M $19.78M $14.00M
Total Long-Term Liabilities $1.968M $1.923M $3.800M
Total Liabilities $26.21M $26.68M $17.70M
YoY Change 50.09% 50.75% 55.26%
SHAREHOLDERS EQUITY
Retained Earnings -$285.2M -$265.3M
YoY Change 71.91%
Common Stock $4.000K $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $105.8M $116.5M $85.94M
YoY Change
Total Liabilities & Shareholders Equity $132.0M $143.2M $103.7M
YoY Change -38.97% 38.09% -37.68%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$19.93M -$32.83M -$23.92M
YoY Change -13.84% 37.25% 109.29%
Depreciation, Depletion And Amortization $120.0K $90.00K $50.00K
YoY Change 50.0% 80.0% 400.0%
Cash From Operating Activities -$17.69M -$24.15M -$21.40M
YoY Change -28.03% 12.85% 132.86%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$100.0K -$620.0K
YoY Change -95.65% -83.87% 933.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$2.610M
YoY Change
Cash From Investing Activities -$50.00K -$2.710M -$620.0K
YoY Change -95.65% 337.1% 933.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.410M 220.0K 0.000
YoY Change -98.95% -100.0%
NET CHANGE
Cash From Operating Activities -17.69M -24.15M -21.40M
Cash From Investing Activities -50.00K -2.710M -620.0K
Cash From Financing Activities 1.410M 220.0K 0.000
Net Change In Cash -16.33M -26.64M -22.02M
YoY Change -114.99% 20.98% -123.64%
FREE CASH FLOW
Cash From Operating Activities -$17.69M -$24.15M -$21.40M
Capital Expenditures -$50.00K -$100.0K -$620.0K
Free Cash Flow -$17.64M -$24.05M -$20.78M
YoY Change -24.71% 15.74% 127.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
dei Entity Central Index Key
EntityCentralIndexKey
0001722964
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38650
dei Entity Registrant Name
EntityRegistrantName
Y-mAbs Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4619612
dei Entity Address Address Line1
EntityAddressAddressLine1
230 Park Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3350
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10169
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
885-8505
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
YMAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40513657
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4819000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1942000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
133209000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131267000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
207136000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
211955000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1888000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2052000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5123000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1989000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2975000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
370000
CY2020Q3 us-gaap Assets
Assets
143195000
CY2019Q4 us-gaap Assets
Assets
216366000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10320000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8520000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7570000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4550000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1887000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
516000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19777000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13586000
CY2020Q3 ymab Accrued Milestone And Royalty Payments Noncurrent
AccruedMilestoneAndRoyaltyPaymentsNoncurrent
2466000
CY2019Q4 ymab Accrued Milestone And Royalty Payments Noncurrent
AccruedMilestoneAndRoyaltyPaymentsNoncurrent
1921000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2517000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1714000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1923000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
242000
CY2020Q3 us-gaap Liabilities
Liabilities
26683000
CY2019Q4 us-gaap Liabilities
Liabilities
17463000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40472435
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39728416
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
381803000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
364712000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
50000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265267000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165863000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
116512000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
198903000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143195000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1354000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32832000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
56000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-23922000
us-gaap Net Income Loss
NetIncomeLoss
-99404000
us-gaap Net Income Loss
NetIncomeLoss
-57892000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-12000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
134000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-78000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
124000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
864000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
216366000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21005000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19660000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69686000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46665000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11636000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4699000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30155000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12581000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
32641000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
24359000
us-gaap Operating Expenses
OperatingExpenses
99841000
us-gaap Operating Expenses
OperatingExpenses
59246000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32641000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24359000
us-gaap Operating Income Loss
OperatingIncomeLoss
-99841000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59246000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-191000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
437000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
437000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32844000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23788000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99482000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57768000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.69
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40187173
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34371927
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39971766
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34253739
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
140527000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-15934000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
125513000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
971000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-66000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-18036000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
134000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-23922000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2262000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
108382000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1345000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
85939000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
131000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1800000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
198903000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
370000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2211000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26179000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
175330000
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
8707000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2455000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-91000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-40393000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
146008000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3133000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32832000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
116512000
us-gaap Profit Loss
ProfitLoss
-99404000
us-gaap Profit Loss
ProfitLoss
-57892000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
279000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
us-gaap Share Based Compensation
ShareBasedCompensation
7799000
us-gaap Share Based Compensation
ShareBasedCompensation
3180000
ymab Noncash Stock Issuance Costs To Strategic Partner
NoncashStockIssuanceCostsToStrategicPartner
1331000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
7376000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
62000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-123000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1939000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1031000
ymab Increase Decrease In Accrued Liabilities And Other
IncreaseDecreaseInAccruedLiabilitiesAndOther
5404000
ymab Increase Decrease In Accrued Liabilities And Other
IncreaseDecreaseInAccruedLiabilitiesAndOther
2422000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73536000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48918000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
818000
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
2610000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2741000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-818000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
585000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
585000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-177000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75869000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49679000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
207136000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147871000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
ymab Number Of Votes Per Common Stock
NumberOfVotesPerCommonStock
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34372000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39972000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34254000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.49
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
901000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.69
CY2019 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40472435
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39728416
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131267000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98192000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2679000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
752000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1—ORGANIZATION AND DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Y-mAbs Therapeutics, Inc. (“we,” “us,” “our,” the “Company,” or “Y-mAbs”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is headquartered in New York, New York and was incorporated on April 30, 2015 under the laws of the State of Delaware.</p>
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 2—BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development; technological uncertainty; uncertainty regarding patents and proprietary rights; uncertainty in obtaining FDA approval in the United States and regulatory approval in other jurisdictions; marketing or sales capability or experience; uncertainty in getting adequate payer coverage and reimbursement; dependence on key personnel; compliance with government regulations and the need to obtain additional financing. The Company’s drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s drug candidates are in various stages of development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations since inception and had an accumulated deficit of $265.3 million as of September 30, 2020 and $165.9 million as of December 31, 2019. Through September 30, 2020, the Company has funded its operations through proceeds from sales of shares of its common stock, including its initial public offering in September 2018 and its secondary public offering in November 2019. The future viability of the Company, until such time that the Company has commercialized any of its products, is dependent on its ability to raise additional capital to finance its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company had cash and cash equivalents of $131.3 million. As of the issuance date of the quarterly financial statements as of and for the nine months ended September 30, 2020, the Company expects that its cash and cash equivalents at September 30, 2020 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next twelve months, irrespective of whether any product approvals are obtained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company may raise additional capital to fund future operations through the sale of its equity securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company on attractive terms or at all when needed from equity or debt financing. If FDA approvals for naxitamab or omburtamab do not occur or are significantly delayed, and the Company is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">unable to obtain additional financing from these or other sources when needed, it will likely be necessary to take other actions to enhance its liquidity position which may include significantly reducing the current rate of spending through delaying, scaling back current operations, or suspending certain research and development programs and other operational programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited consolidated financial statements reflect the accounts of the Company and its wholly-<span style="white-space:pre-wrap;">owned subsidiary and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, Accounting Standards Codification (“ASC”) Topic 270-10 and with the instructions to Form 10-Q. Accordingly, these financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements include all adjustments (consisting only of normal recurring nature) necessary in the judgment of management for a fair statement of the results for the periods presented. All intercompany balances and transactions have been eliminated. The Company has evaluated subsequent events through the date of this filing. Operating results for the three and nine-month periods ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020, any other interim periods, or any future year or period. The December 31, 2019 consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. You should read these unaudited interim condensed consolidated financial statements in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></p>
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265300000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165900000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131300000
CY2020Q3 us-gaap Residual Value Of Leased Asset
ResidualValueOfLeasedAsset
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses, the accrual of milestone and royalty payments, and the valuation of stock options. Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
335000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-23922000
us-gaap Net Income Loss
NetIncomeLoss
-99404000
us-gaap Net Income Loss
NetIncomeLoss
-57892000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40187000
CY2020Q3 ymab Accrued Compensation And Board Fees Current
AccruedCompensationAndBoardFeesCurrent
3853000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32832000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5056288
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4124169
CY2019Q4 ymab Accrued Compensation And Board Fees Current
AccruedCompensationAndBoardFeesCurrent
1475000
CY2020Q3 ymab Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
1319000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 ymab Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
729000
CY2019Q4 ymab Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
760000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 ymab Accrued Licensing Milestone And Royalty Payments Current
AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent
1334000
CY2019Q4 ymab Accrued Licensing Milestone And Royalty Payments Current
AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent
354000
CY2019Q4 ymab Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1584000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
377000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7570000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4550000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
330000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
174000
us-gaap Operating Lease Cost
OperatingLeaseCost
680000
us-gaap Operating Lease Cost
OperatingLeaseCost
502000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
201000
us-gaap Operating Lease Payments
OperatingLeasePayments
594000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
541000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2168000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1587000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
540000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
64000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4900000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
496000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4404000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
749000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
753000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
646000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
539000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
77000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2764000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
534000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2230000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M1D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2020Q3 ymab Total Shares Authorized
TotalSharesAuthorized
105500000
CY2019Q4 ymab Total Shares Authorized
TotalSharesAuthorized
105500000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4005873
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.67
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
82944000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1196000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.98
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
83694
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89667
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5028512
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.50
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
113742000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M3D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2900840
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.81
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
91617000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M19D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.72
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
155000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.34
CY2019Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32800000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23900000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-99400000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57900000
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2019Q3 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2020Q3 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0

Files In Submission

Name View Source Status
0001558370-20-012905-index-headers.html Edgar Link pending
0001558370-20-012905-index.html Edgar Link pending
0001558370-20-012905.txt Edgar Link pending
0001558370-20-012905-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ymab-20200930.xsd Edgar Link pending
ymab-20200930x10q.htm Edgar Link pending
ymab-20200930x10q_htm.xml Edgar Link completed
ymab-20200930xex10d8.htm Edgar Link pending
ymab-20200930xex10d9.htm Edgar Link pending
ymab-20200930xex31d1.htm Edgar Link pending
ymab-20200930xex31d2.htm Edgar Link pending
ymab-20200930xex32d1.htm Edgar Link pending
ymab-20200930xex32d2.htm Edgar Link pending
ymab-20200930_cal.xml Edgar Link unprocessable
ymab-20200930_def.xml Edgar Link unprocessable
ymab-20200930_lab.xml Edgar Link unprocessable
ymab-20200930_pre.xml Edgar Link unprocessable